Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 615

The DOI matches its Crossref record.

American Urological Association Guideline On The Management of Priapism

MONTAGUE, DROGO K., JAROW, JONATHAN, BRODERICK, GREGORY A., DMOCHOWSKI, ROGER R., HEATON, JEREMY P.W., LUE, TOM F., NEHRA, AJAY, SHARLIP, IRA D., MEMBERS OF THE ERECTILE DYSFUNCTION GUIDELINE UPDATE PANEL·2003·Journal of Urology

Abstract

No AccessJournal of UrologyCLINICAL UROLOGY: Special Communications1 Oct 2003American Urological Association Guideline On The Management of Priapism DROGO K. MONTAGUE, JONATHAN JAROW, GREGORY A. BRODERICK, ROGER R. DMOCHOWSKI, JEREMY P.W. HEATON, TOM F. LUE, AJAY NEHRA, IRA D. SHARLIP, and MEMBERS OF THE ERECTILE DYSFUNCTION GUIDELINE UPDATE PANEL‡‡ DROGO K. MONTAGUEDROGO K. MONTAGUE Financial interests/and or relationship with American Medical Systems, Bayer, Lilly-ICOS and Pfizer. More articles by this author , JONATHAN JAROWJONATHAN JAROW Financial interest and/or other relationship with Pfizer and Bayer. More articles by this author , GREGORY A. BRODERICKGREGORY A. BRODERICK Financial interest and/or other relationship with Bayer, Eli Lilly/ICOS, Mentor Corp. Abbott/Tap and Pfizer. More articles by this author , ROGER R. DMOCHOWSKIROGER R. DMOCHOWSKI Financial interest and/or other relationship with Ortho-McNeil Pharmaceuticals, Watson and Indevus. More articles by this author , JEREMY P.W. HEATONJEREMY P.W. HEATON Financial interests/and or relationship with AGGSH International, Cellegy and TAP. More articles by this author , TOM F. LUETOM F. LUE Financial interest and/or other relationship with Pfizer, Lilly/ICOS, Bayer-GlaxoSmithKline and Tap. More articles by this author , AJAY NEHRAAJAY NEHRA Financial interest and/or other relationship with Bayer and Pfizer. More articles by this author , IRA D. SHARLIPIRA D. SHARLIP Financial interest and/or other relationship with Pfizer, Lilly/ICOS, Bayer, Tap and NexMed. More articles by this author , and MEMBERS OF THE ERECTILE DYSFUNCTION GUIDELINE UPDATE PANEL‡‡ Consultants: Hanan S. Bell, Patrick M. Florer and Charles B. Hathaway. More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000087608.07371.caAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1 : Low-flow priapism: risk factors for erectile dysfunction. BJU Int2002; 89: 285. Google Scholar 2 : The ultrastructure of erectile tissue in priapism. J Urol1986; 135: 142. Link, Google Scholar 3 : Pharmacologic erection: time-dependent changes in the corporal environment. Int J Impot Res1994; 6: 9. Google Scholar 4 : Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. Edited by . New York: McGraw-Hill Professional Publishing, chapt. 102001: 215. Google Scholar 5 : Priapism. In: Glenn's Urologic Surgery. Edited by . Philadelphia: Lippincott Williams & Wilkins1998. Google Scholar 6 : Atlas of Urologic Surgery. Philadelphia: W. B. Saunders Co.1998: 177. sect. 6. Google Scholar 7 : Permanent open shunt as a reason for impotence or reduced potency after surgical treatment of priapism in 26 patients. Int J Impot Res1995; 7: 175. Google Scholar 8 : Priapism. Our experience. Arch Esp Urol1998; 51: 269. Google Scholar 9 : Pulmonary embolism: a complication of corpus-saphenous shunt for priapism. J Urol1968; 99: 196. Link, Google Scholar 10 : Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections. Urology1993; 42: 51. Google Scholar 11 : High flow priapism complicating veno-occlusive priapism: pathophysiology of recurrent idiopathic priapism?. J Urol1998; 159: 1300. Link, Google Scholar 12 : Pathophysiology of “low flow” priapism: intermediate phase-evidence of “high flow” defined with duplex ultrasound. Int J Impot Res1999; 11: S27. Google Scholar 13 : Arterial priapism: diagnosis, treatment and long-term followup. J Urol1994; 151: 1231. Link, Google Scholar 14 : Use of methylene blue and selective embolization of the pudendal artery for high flow priapism refractory to medical and surgical treatments. J Urol1991; 146: 1361. Link, Google Scholar 15 : Short period of administration of diethylstilbestrol in stuttering priapism in sickle cell anemia. Am J Hematol2002; 69: 297. Google Scholar 16 : Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology1996; 47: 777. Google Scholar 17 : Antiandrogens in the treatment of priapism. Urology2002; 59: 138. Google Scholar 18 : Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism. J Urol1993; 150: 475. Link, Google Scholar 19 : Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet1985; 2: 1274. Google Scholar 20 : Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue. J Urol1995; 153: 152. Link, Google Scholar 21 : Treatment of recurrent idiopathic priapism. J Urol2002; 168: 2552. Link, Google Scholar 22 : A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity. J Urol1998; 159: 1529. Link, Goo

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.ju.0000087608.07371.ca

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 22

  1. El-Bahnasawy, 2002, Low-flow priapism: risk factors for erectile dysfunction, BJU Int, 89, 285, 10.1046/j.1464-4096.2001.01510.x · DOI
  2. Spycher, 1986, The ultrastructure of erectile tissue in priapism, J Urol, 135, 142, 10.1016/S0022-5347(17)45549-2 · DOI
  3. Broderick, 1994, Pharmacologic erection: time-dependent changes in the corporal environment, Int J Impot Res, 6, 9
  4. Kulmala, 1995, Permanent open shunt as a reason for impotence or reduced potency after surgical treatment of priapism in 26 patients, Int J Impot Res, 7, 175
  5. Urdangarain, 1998, Priapism. Our experience, Arch Esp Urol, 51, 269
  6. Kandel, 1968, Pulmonary embolism: a complication of corpus-saphenous shunt for priapism, J Urol, 99, 196, 10.1016/S0022-5347(17)62672-7 · DOI
  7. Lowe, 1993, Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections, Urology, 42, 51, 10.1016/0090-4295(93)90338-B · DOI
  8. Seftel, 1998, High flow priapism complicating veno-occlusive priapism: pathophysiology of recurrent idiopathic priapism?, J Urol, 159, 1300, 10.1016/S0022-5347(01)63590-0 · DOI
  9. Matson, 1999, Pathophysiology of “low flow” priapism: intermediate phase-evidence of “high flow” defined with duplex ultrasound, Int J Impot Res, 11, S27
  10. Bastuba, 1994, Arterial priapism: diagnosis, treatment and long-term followup, J Urol, 151, 1231, 10.1016/S0022-5347(17)35219-9 · DOI
  11. Steers, 1991, Use of methylene blue and selective embolization of the pudendal artery for high flow priapism refractory to medical and surgical treatments, J Urol, 146, 1361, 10.1016/S0022-5347(17)38095-3 · DOI
  12. Gbadoe, 2002, Short period of administration of diethylstilbestrol in stuttering priapism in sickle cell anemia, Am J Hematol, 69, 297, 10.1002/ajh.10069 · DOI
  13. Virag, 1996, Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine, Urology, 47, 777, 10.1016/S0090-4295(96)00027-1 · DOI
  14. Dahm, 2002, Antiandrogens in the treatment of priapism, Urology, 59, 138, 10.1016/S0090-4295(01)01492-3 · DOI
  15. Levine, 1993, Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism, J Urol, 150, 475, 10.1016/S0022-5347(17)35520-9 · DOI
  16. Serjeant, 1985, Stilboestrol and stuttering priapism in homozygous sickle-cell disease, Lancet, 2, 1274, 10.1016/S0140-6736(85)91555-7 · DOI
  17. Steinberg, 1995, Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue, J Urol, 153, 152, 10.1097/00005392-199501000-00054 · DOI
  18. Rourke, 2002, Treatment of recurrent idiopathic priapism, J Urol, 168, 2552, 10.1016/S0022-5347(05)64201-2 · DOI
  19. Gupta, 1998, A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity, J Urol, 159, 1529, 10.1097/00005392-199805000-00033 · DOI
  20. Ahmed, 1997, Treatment of intermittent idiopathic priapism with oral terbutaline, Br J Urol, 80, 341, 10.1046/j.1464-410X.1997.00285.x · DOI
  21. Gbadoe, 2001, Management of sickle cell priapism with etilefrine, Arch Dis Child, 85, 52, 10.1136/adc.85.1.52 · DOI
  22. van Driel, 1990, Intracorporeal self-injection with epinephrine as treatment for idiopathic recurrent priapism, Eur Urol, 17, 95, 10.1159/000464011 · DOI

Cited by

Metadata

Authors
MONTAGUE, D. K., JAROW, J., BRODERICK, G. A., DMOCHOWSKI, R. R., HEATON, J. P. W., LUE, T. F., NEHRA, A., SHARLIP, I. D., & PANEL, M. O. T. E. D. G. U.
Venue
Journal of Urology
Published
2003-10
Volume
170
Issue
4 Part 1
Pages
1318-1324
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2143379701
Cited by
615
References
0
FWCI
5.26
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.